Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02184195
Registration number
NCT02184195
Ethics application status
Date submitted
6/06/2014
Date registered
9/07/2014
Date last updated
13/09/2023
Titles & IDs
Public title
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Query!
Scientific title
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Query!
Secondary ID [1]
0
0
2014-001589-85
Query!
Secondary ID [2]
0
0
D081FC00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
POLO
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Germline BRCA1/2 Mutations and
0
0
Query!
Metastatic Adenocarcinoma of the Pancreas
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Pancreatic
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Olaparib
Treatment: Drugs - Olaparib
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo
Experimental: Olaparib - Olaparib tablets po. 300 mg twice daily
Placebo Comparator: Placebo - Placebo tablets twice daily
Treatment: Drugs: Olaparib
Tablet -100mg
Treatment: Drugs: Olaparib
Tablet-150mg
Treatment: Drugs: Placebo
Match Olaparib 100mg placebo
Treatment: Drugs: Placebo
Match Olaparib 150mg placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1)
Query!
Assessment method [1]
0
0
To determine the efficacy of olaparib maintenance monotherapy compared to placebo by PFS. The PFS was defined as the time from randomisation until the date of objective radiological disease progression according to modified RECIST v1.1 or death (by any cause in the absence of disease progression) regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to disease progression.
Query!
Timepoint [1]
0
0
Up to 4 years
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
To determine the efficacy by assessment of OS of olaparib maintenance monotherapy compared to placebo. The OS was defined as the time from the date of randomization until death due to any cause.
Query!
Timepoint [1]
0
0
Upto 4 years
Query!
Secondary outcome [2]
0
0
Time From Randomisation to Second Progression (PFS2)
Query!
Assessment method [2]
0
0
To determine efficacy by assessment of PFS2 of olaparib maintenance monotherapy compared to placebo. The PFS2 was defined as the time from the date of randomisation to the earliest of the progression event subsequent to that used for the primary variable PFS or death.
Query!
Timepoint [2]
0
0
Up to 4 years
Query!
Secondary outcome [3]
0
0
Time From Randomisation to Second Subsequent Therapy or Death (TSST)
Query!
Assessment method [3]
0
0
To determine the efficacy by assessment of TSST of olaparib maintenance monotherapy compared to placebo. The TSST was defined as time to second subsequent therapy or death.
Query!
Timepoint [3]
0
0
Up to 4 years
Query!
Secondary outcome [4]
0
0
Time From Randomisation to First Subsequent Therapy or Death (TFST)
Query!
Assessment method [4]
0
0
To determine the efficacy by assessment of TFST of olaparib maintenance monotherapy compared to placebo. The TFST was defined as time to first subsequent therapy or death.
Query!
Timepoint [4]
0
0
Up to 4 years
Query!
Secondary outcome [5]
0
0
Time From Randomisation to Study Treatment Discontinuation or Death (TDT)
Query!
Assessment method [5]
0
0
To determine the efficacy by assessment of TDT compared to placebo. compared to placebo. The TDT was defined as time to study treatment discontinuation or death.
Query!
Timepoint [5]
0
0
Up to 4 years
Query!
Secondary outcome [6]
0
0
Number of Participants With Objective Response Rate (ORR) by BICR Using Modified RECIST 1.1
Query!
Assessment method [6]
0
0
To determine efficacy by assessment of objective response rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo. The ORR is defined as the number of with a BoR of CR and PR according to the BICR data divided by the number of patients in the treatment group with measurable disease at baseline.
Query!
Timepoint [6]
0
0
Up to 4 years
Query!
Secondary outcome [7]
0
0
Disease Control Rate (DCR) by BICR Using Modified RECIST 1.1
Query!
Assessment method [7]
0
0
Efficacy by assessment of disease control rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo.
Query!
Timepoint [7]
0
0
At 16 weeks
Query!
Secondary outcome [8]
0
0
Adjusted Mean Change From Baseline up to 6 Months in Global Quality of Life (QoL) Score From the EORTC-QLQ-C30 Questionnaire
Query!
Assessment method [8]
0
0
To assess the effect of olaparib on health-related quality of life (QoL) as measured by the EORTC-QLQ-C30 global QoL scale. The EORTC-QLQ-C30 is defined as EORTC QLQ-C30: a questionnaire (30 questions) used to evaluate disease symptoms, functional impacts (eg, physical functioning), and HRQoL and to characterize clinical benefit from the patient perspective. The HRQoL score ranges from 0 to 100.
A higher score indicates better QoL. A score change of 10 points was pre-defined as clinically meaningful.
bd twice daily.
Query!
Timepoint [8]
0
0
From baseline up to 6 months
Query!
Secondary outcome [9]
0
0
Number of Participants With Adverse Events (AEs)
Query!
Assessment method [9]
0
0
To assess the safety and tolerability of olaparib maintenance monotherapy. SAE: serious adverse events CTCAE: Common Terminology Criteria for Adverse Events
Query!
Timepoint [9]
0
0
Up to 4 years
Query!
Eligibility
Key inclusion criteria
Key Inclusion Criteria
- Histologically or cytologically confirmed pancreas adenocarcinoma receiving initial
chemotherapy for metastatic disease and without evidence of disease progression on
treatment
- Patients with measurable disease and/or non-measurable or no evidence of disease
assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in
this study.
- Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or
suspected deleterious
- Patients are on treatment with a first line platinum-based (cisplatin, carboplatin or
oxaliplatin) regimen for metastatic pancreas cancer, have received a minimum of 16
weeks of continuous platinum treatment and have no evidence of progression based on
investigator's opinion.
- Patients who have received platinum as potentially curative treatment for a prior
cancer (eg ovarian cancer) or as adjuvant/neoadjuvant treatment for pancreas cancer
are eligible provided at least 12 months have elapsed between the last dose of
platinum-based treatment and initiation of the platinum-based chemotherapy for
metastatic pancreas cancer.
Major
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
130
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- gBRCA1 and/or gBRCA2 mutations that are considered to be non detrimental (eg,
"Variants of uncertain clinical significance" or "Variant of unknown significance" or
"Variant, favour polymorphism" or "benign polymorphism" etc.)
- Progression of tumour between start of first line platinum based chemotherapy for
metastatic pancreas cancer and randomisation.
- Cytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle
1 Day 1 is not permitted.
- Exposure to an investigational product within 30 days or 5 half lives (whichever is
longer) prior to randomisation
- Any previous treatment with a PARP inhibitor, including Olaparib
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/12/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
27/01/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
154
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Campbelltown
Query!
Recruitment hospital [2]
0
0
Research Site - Randwick
Query!
Recruitment hospital [3]
0
0
Research Site - St Leonards
Query!
Recruitment postcode(s) [1]
0
0
2560 - Campbelltown
Query!
Recruitment postcode(s) [2]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [3]
0
0
2065 - St Leonards
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Missouri
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Washington
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Antwerpen
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Brussel
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Leuven
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Ontario
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Quebec
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Toronto
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Amiens
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Besançon
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Bordeaux
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Brest Cedex
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Clichy Cedex
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
La Roche sur Yon
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Lille
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Lyon Cedex 03
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Nice
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Paris CEDEX 14
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Paris
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Poitiers
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
STRASBOURG Cedex
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Toulouse
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Villejuif
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Berlin
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Bochum
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Bonn
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Dresden
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Frankfurt am Main
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Hamburg
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Hannover
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Leipzig
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
München
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Schweinfurt
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Ulm
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Beer Sheva
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Haifa
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Holon
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Nahariya
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Petah Tikva
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Ramat Gan
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Rehovot
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Tel Aviv
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Zefir
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Bologna
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Milano
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Padova
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Parma
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Pescara
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Roma
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
San Giovanni Rotondo
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Verona
Query!
Country [64]
0
0
Korea, Republic of
Query!
State/province [64]
0
0
Seongnam-si
Query!
Country [65]
0
0
Korea, Republic of
Query!
State/province [65]
0
0
Seoul
Query!
Country [66]
0
0
Netherlands
Query!
State/province [66]
0
0
Amsterdam
Query!
Country [67]
0
0
Spain
Query!
State/province [67]
0
0
Barcelona
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Girona
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
L'Hospitalet de Llobregat
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Madrid
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Málaga
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Pamplona
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Sabadell
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Santiago de Compostela
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Valencia
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Zaragoza
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
Edinburgh
Query!
Country [78]
0
0
United Kingdom
Query!
State/province [78]
0
0
Glasgow
Query!
Country [79]
0
0
United Kingdom
Query!
State/province [79]
0
0
Liverpool
Query!
Country [80]
0
0
United Kingdom
Query!
State/province [80]
0
0
London
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Manchester
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
Northwood
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Nottingham
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Surrey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Myriad Genetic Laboratories, Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Commercial sector/Industry
Query!
Name [2]
0
0
Merck Sharp & Dohme LLC
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance
Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose
Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02184195
Query!
Trial related presentations / publications
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algul H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02184195
Download to PDF